Actinic keratosis (AK) and basal cell carcinoma (BCC) are very common diseases, both skin disorders associated with overexposure of sunlight. AK is by far the most prevalent skin cancer condition affecting up to 60 million people in the US alone, and BCC is the most common type of skin cancer, with estimated 4 million new cases each year in the US alone.
There are few drug therapies available and most are associated with moderate to severe side effects. Hence we see a market opportunity for a safe and efficacious treatment with our clinically validated drug candidate AVX001.
BCC is the most common type of skin cancer with a global annual sale of 6.7 billion USD.
Erlend P. Skagseth
Chairman of the Board
John R. Zibert